VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
This Quarter Return
-5.48%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$97.2M
AUM Growth
+$97.2M
(-16%)
Cap. Flow
+$17.2M
Cap. Flow
% of AUM
17.74%
Top 10 Holdings %
Top 10 Hldgs %
76.66%
Holding
55
New
10
Increased
17
Reduced
2
Closed
8
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$8.32M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$2.86M |
| 3 |
Zevra Therapeutics
ZVRA
|
$2.73M |
| 4 |
scPharmaceuticals
SCPH
|
$2.41M |
| 5 |
Mineralys Therapeutics
MLYS
|
$2.39M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$4.36M |
| 2 |
Nurix Therapeutics
NRIX
|
$1.84M |
| 3 |
Kura Oncology
KURA
|
$1.31M |
| 4 |
Rezolute
RZLT
|
$1.16M |
| 5 |
Collegium Pharmaceutical
COLL
|
$822K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tenax Therapeutics
TENX
$27.3M
| $546K | 0.56% |
83,333
| – | – |
|
27
Kiora Pharmaceuticals
KPRX
$9.55M
| $368K | 0.38% |
122,223
| – | – |
|
28
Corbus Pharmaceuticals
CRBP
$115M
| $313K | 0.32% |
59,000
+2,300
| +4% | +$12.2K |
|
|
RGLS
29
DELISTED
Regulus Therapeutics
RGLS
| $140K | 0.14% |
80,000
+10,000
| +14% | +$17.5K |
|
30
Wave Life Sciences
WVE
$1.53B
| $105K | 0.11% |
13,000
| – | – |
|
31
Gossamer Bio
GOSS
$589M
| $82.5K | 0.08% |
75,000
| – | – |
|
32
Erasca
ERAS
$454M
| $68.5K | 0.07% |
+50,000
| New | +$68.5K |
|
33
Alector
ALEC
$262M
| $67.7K | 0.07% |
55,000
| – | – |
|
34
Larimar Therapeutics
LRMR
$318M
| $60.2K | 0.06% |
28,000
+10,000
| +56% | +$21.5K |
|
35
ProQR Therapeutics
PRQR
$237M
| $59.9K | 0.06% |
45,000
+4,500
| +11% | +$5.99K |
|
36
Context Therapeutics
CNTX
$76.2M
| $55.1K | 0.06% |
90,000
| – | – |
|
37
Design Therapeutics
DSGN
$315M
| $54K | 0.06% |
+14,000
| New | +$54K |
|
38
Aclaris Therapeutics
ACRS
$216M
| $53.6K | 0.06% |
35,000
+8,000
| +30% | +$12.2K |
|
39
CytomX Therapeutics
CTMX
$343M
| $47.7K | 0.05% |
75,000
+40,000
| +114% | +$25.4K |
|
40
Terns Pharmaceuticals
TERN
$662M
| $46.9K | 0.05% |
17,000
| – | – |
|
41
Ventyx Biosciences
VTYX
$175M
| $46K | 0.05% |
40,000
+5,000
| +14% | +$5.75K |
|
42
4D Molecular Therapeutics
FDMT
$287M
| $38.8K | 0.04% |
12,000
+2,000
| +20% | +$6.46K |
|
43
PMV Pharmaceuticals
PMVP
$79M
| $38.2K | 0.04% |
35,000
| – | – |
|
44
Ovid Therapeutics
OVID
$87.5M
| $30.3K | 0.03% |
97,000
+27,000
| +39% | +$8.42K |
|
|
KRON
45
DELISTED
Kronos Bio
KRON
| $28.9K | 0.03% |
35,000
| – | – |
|
46
NextCure
NXTC
$13.5M
| $12K | 0.01% |
25,000
| – | – |
|
|
ELEV
47
DELISTED
Elevation Oncology
ELEV
| $11.7K | 0.01% |
45,000
| – | – |
|
|
48
Collegium Pharmaceutical
COLL
$1.22B
| – | – |
-28,685
| Closed | -$822K |
|
49
Enanta Pharmaceuticals
ENTA
$180M
| – | – |
-13,000
| Closed | -$74.8K |
|
50
FibroGen
FGEN
$47.8M
| – | – |
-80,000
| Closed | -$42.4K |
|